Second-generation antipsychotics are usually seen as an important step forward in the treatment of schizophrenia but can lead to weight gain, high cholesterol, type 2 diabetes and cardiovascular problems. One solution for patients at risk of these conditions is to switch to another drug. Amisulpride has been shown to be linked to less weight gain in the past and a team of researchers from Taiwan studied the effect of switching to it in research involving 92 participants half of whom switched to the drug and half of whom stuck with their original medication. The study found that the participants who switched to amisulpride had less cholesterol and insulin resistance, decreased blood pressure and more beneficial cholesterol.
Lin, Chao-Cheng ... [et al] - Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics Journal of Clinical Psychopharmacology December 2009, 29(6), 529-536